2-Methoxyestradiol Ameliorates Angiotensin II–Induced Hypertension by Inhibiting Cytosolic Phospholipase A 2 α Activity in Female Mice
Open Access
- 11 October 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 78 (5) , 1368-1381
Abstract
We tested the hypothesis that CYP1B1 (cytochrome P450 1B1)-17β-estradiol metabolite 2-methoxyestradiol protects against Ang II (angiotensin II)–induced hypertension by inhibiting group IV cPLA 2 α (cytosolic phospholipase A 2 α) activity and production of prohypertensive eicosanoids in female mice. Ang II (700 ng/kg per minute, SC) increased mean arterial blood pressure (BP), systolic and diastolic BP measured by radiotelemetry, renal fibrosis, and reactive oxygen species production in wild-type mice ( cPLA 2 α +/+ /Cyp1b1 +/+ ) that were enhanced by ovariectomy and abolished in intact and ovariectomized -cPLA 2 α −/− /Cyp1b1 +/+ mice. Ang II–induced increase in SBP measured by tail-cuff, renal fibrosis, reactive oxygen species production, and cPLA 2 α activity measured by its phosphorylation in the kidney, and urinary excretion of prostaglandin E 2 and thromboxane A 2 metabolites were enhanced in ovariectomized- cPLA 2 α +/+ /Cyp1b1 +/+ and intact cPLA 2 α +/+ /Cyp1b1 −/− mice. 2-Methoxyestradiol and arachidonic acid metabolism inhibitor 5,8,11,14-eicosatetraynoic acid attenuated the Ang II–induced increase in SBP, renal fibrosis, reactive oxygen species production, and urinary excretion of prostaglandin E 2 , and thromboxane A 2 metabolites in ovariectomized- cPLA 2 α +/+ /Cyp1b1 +/+ and intact cPLA 2 α +/+ /Cyp1b1 −/− mice. Antagonists of prostaglandin E 2 and thromboxane A 2 receptors EP1 and EP3 and TP, respectively, inhibited Ang II–induced increases in SBP and reactive oxygen species production and renal fibrosis in ovariectomized- cPLA 2 α +/+ /Cyp1b1 +/+ and intact cPLA 2 α +/+ /Cyp1b1 −/− mice. These data suggest that CYP1B1-generated metabolite 2-methoxyestradiol mitigates Ang II–induced hypertension and renal fibrosis by inhibiting cPLA 2 α activity, reducing prostaglandin E 2 , and thromboxane A 2 production and stimulating EP1 and EP3 and TP receptors, respectively. Thus, 2-methoxyestradiol and the drugs that selectively block EP1 and EP3 and TP receptors could be useful in treating hypertension and its pathogenesis in females.Keywords
This publication has 57 references indexed in Scilit:
- 2-Methoxyestradiol inhibits experimental autoimmune encephalomyelitis through suppression of immune cell activationProceedings of the National Academy of Sciences, 2012
- Sex differences in primary hypertensionBiology of Sex Differences, 2012
- Renal NOS activity, expression, and localization in male and female spontaneously hypertensive ratsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2010
- Potential vascular actions of 2-methoxyestradiolTrends in Endocrinology & Metabolism, 2009
- Fetal MouseCyp1b1and Transplacental Carcinogenesis from Maternal Exposure to Dibenzo(a,l)pyreneCancer Prevention Research, 2008
- Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targetingJournal of Clinical Investigation, 2007
- Sex differences in the development of angiotensin II-induced hypertension in conscious miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Role of Pressure in Angiotensin II-Induced Renal InjuryHypertension, 2004
- Role for Thromboxane Receptors in Angiotensin-II–Induced HypertensionHypertension, 2004
- Thromboxane mediates renal hemodynamic response to infused angiotensin IIKidney International, 1991